Nuvation Bio achieved a transformative year in 2024, marked by the FDA's acceptance and Priority Review of the NDA for taletrectinib, setting the stage for a potential U.S. commercial launch in mid-2025. The company also reported a strong balance sheet with $502.7 million in cash, cash equivalents, and marketable securities as of December 31, 2024, and secured up to $250 million in non-dilutive financings.

Nuvation Bio reported a net loss of $41.2 million, or $(0.15) per share, and had cash, cash equivalents, and marketable securities of $549.1 million as of September 30, 2024. The company completed the NDA submission for taletrectinib and presented positive data from Phase 2 TRUST-I and TRUST-II studies.

Nuvation Bio reported a net loss of $462.5 million, or $(1.89) per share, for the three months ended June 30, 2024. As of June 30, 2024, Nuvation Bio had cash, cash equivalents and marketable securities of $577.2 million.

Nuvation Bio reported its Q1 2024 financial results, highlighting the acquisition of AnHeart Therapeutics and the treatment of the first patient in a Phase 1/2 study of NUV-1511. The company's cash, cash equivalents, and marketable securities totaled $597.0 million as of March 31, 2024. The net loss for the quarter was $14.8 million, or $(0.07) per share.

Nuvation Bio reported a net loss of $13.8 million, or $(0.06) per share, for the three months ended December 31, 2023. The company's cash, cash equivalents and marketable securities totaled $611.2 million as of December 31, 2023.

Nuvation Bio reported a net loss of $19.6 million, or $(0.09) per share, and had cash, cash equivalents and marketable securities of $619.3 million as of September 30, 2023.

Nuvation Bio reported a net loss of $20.6 million, or $(0.09) per share, for the second quarter ended June 30, 2023. The company had cash, cash equivalents and marketable securities of $630.9 million as of June 30, 2023.

Nuvation Bio reported a net loss of $21.7 million, or $(0.10) per share, for the first quarter ended March 31, 2023. The company's cash, cash equivalents and marketable securities totaled $646.6 million as of March 31, 2023.

Nuvation Bio reported its Q4 and full year 2022 financial results, highlighting the initiation of dosing in the Phase 1b study of NUV-868 and a strong cash position of $661.0 million.

Nuvation Bio reported a net loss of $27.2 million, or $(0.12) per share, and had cash, cash equivalents and marketable securities of $673.9 million as of September 30, 2022.

Nuvation Bio reported a net loss of $34.9 million, or $0.16 per share, for the three months ended June 30, 2022. The company's cash, cash equivalents and marketable securities totaled $703.8 million as of June 30, 2022.

Nuvation Bio reported a net loss of $21.3 million, or $(0.10) per share for the first quarter ended March 31, 2022. The company had cash, cash equivalents and marketable securities of $737.7 million as of March 31, 2022. The company is focusing on the development of NUV-422, NUV-868, and DDC programs, and has deprioritized NUV-569 and A2A programs.

Nuvation Bio reported a net loss of $25.1 million, or $(0.12) per share, for the three months ended December 31, 2021. As of December 31, 2021, the company had cash, cash equivalents and marketable securities of $765.4 million.

Nuvation Bio reported a net loss for Q3 2021, but highlighted progress in clinical trials for NUV-422 and NUV-868, as well as expansion of their pipeline with new drug candidates.

Nuvation Bio reported a net loss of $19.3 million, or $(0.09) per share, and had cash, cash equivalents and marketable securities of $806.6 million as of June 30, 2021. They are advancing their supply chain and continuing to enroll patients in their Phase 1/2 study of NUV-422.

Nuvation Bio reported a net loss of $20.4 million, or $(0.12) per share, and had cash, cash equivalents, and marketable securities of $824.7 million as of March 31, 2021.